BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Two leading medical stocks that appear reasonable at current levels are AbbVie (NYSE: ABBV) and Merck (NYSE: MRK). The former ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

Firms with significant exposure to federal spending, government contracts and regulatory approvals are now tallying up the ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

The US is the best place for a business to invest, the boss of one of the UK's biggest pharmaceutical companies has said.

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod ...

The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA ...

Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in. Guggenheim lifted the price target on Merck & Co.